Ruxolitinib for the management of myelofibrosis: results of an international physician survey
MH Ellis, M Koren-Michowitz, N Lavi, AM Vannucchi… - Leukemia research, 2017 - Elsevier
Background Ruxolitinib is established as treatment for symptomatic myeloproliferative
neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and
dose modification rules that applied to the COMFORTI and II studies that led to the licensing
of ruxolitinib are not always applicable to routine clinical practice. Thus physicians now face
decisions regarding ruxolitinib use that were not addressed in these pivotal trials. Methods
We performed an online survey of hematologists practicing in Europe, Israel, the United …
neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and
dose modification rules that applied to the COMFORTI and II studies that led to the licensing
of ruxolitinib are not always applicable to routine clinical practice. Thus physicians now face
decisions regarding ruxolitinib use that were not addressed in these pivotal trials. Methods
We performed an online survey of hematologists practicing in Europe, Israel, the United …